Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment versus 300 mg Aspirin® N tablets p.o. (BAY e4465A) in patients with Acute Coronary Syndrome, measured by time dependent thromboxane inhibition https://kusajili.com:443/Trial/ZEiyqJ3x80W6I2h_9TPtDw%24a-prospective-randomized-verum-controlled-open-label-parallel-group-multi-center-phase-iii-clinical-trial-to-demonstrate-the-su
I have read and accept the terms of use of the site and the Privacy Policy
Send your message